vidarabine has been researched along with Dermatitis Medicamentosa in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Creamer, D; Devereux, S; Mufti, G; Perera, GK; Salisbury, J | 1 |
| Blaschke, V; Braess, J; Brinck, U; Dames, K; Letschert, M; Neumann, C; Reich, K; Rünger, TM; Wörmann, B | 1 |
| Allen, J; Amagai, M; Carmichael, AJ; Dean, D; Frith, P; Gooptu, C; Hashimoto, T; Littlewood, TJ; Lyon, CC; MacWhannell, A; Oliwiecki, S; Wojnarowska, F | 1 |
| Pavan-Langston, D | 1 |
2 review(s) available for vidarabine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine | 2009 |
Diagnosis and management of herpes simplex ocular infection.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Child, Preschool; Corneal Ulcer; Debridement; Drug Eruptions; Epithelium; Humans; Idoxuridine; Keratitis; Keratitis, Dendritic; Keratoconjunctivitis; Mydriatics; Recurrence; Uveitis; Vidarabine | 1975 |
1 trial(s) available for vidarabine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
4 other study(ies) available for vidarabine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
PNP with Waldenström's macroglobulinaemia.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Humans; Male; Paraneoplastic Syndromes; Pemphigus; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus.
Topics: Adult; CD8-Positive T-Lymphocytes; Drug Eruptions; Epidermis; Female; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Immunophenotyping; Immunosuppressive Agents; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Lymphoma, Non-Hodgkin; Pemphigus; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 1999 |
Paraneoplastic pemphigus: an association with fludarabine?
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Fluorescent Antibody Technique; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 2001 |